Blood Metabolomics Reveals the Metabolic Disorder in Disease Progression for Patients with Ischemic Heart Disease

Ischemic heart disease is one of the main causes of death worldwide. In this study, the plasma samples of 47 patients with angina, 51 patients with myocardial infarction, and 80 patients with heart failure were collected. Ultra-performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS) and chemometrics were used to analyze the plasma metabolic disorder in disease progression for patients with ischemic heart disease. Chromatographic separation was performed on an ACE3 C18 column (150 mm×3.0 mm×3 μm), and MS analysis was carried out by electrospray ionization (ESI) source at positive and negative modes combined with full scanning. In total, 97 endogenous metabolites were identified and quantitative analyzed. Principal component analysis and partial least square-discriminant analysis were applied in combination with variable importance projection (VIP) and t-test to screen differentially characteristic metabolites. Metabolite concentration was analyzed using SPSS and the metabolites with significant differences (P1 were selected using Variable Importance in Projection screening. Finally, disease-specific metabolites were identified using VIP>1 and t-test P